Condensation products of triethanolamine with addition products of fatty acids, C18 (unsaturated) alkyl with maleic anhydride

Endpoint summary

Key value for chemical safety assessment

Bioaccumulation potential:

no bioaccumulation potential

Additional information

No specific study was performed on the absorption, distribution, metabolism and/or excretion (ADME) of WS400123, a complex mixture of components. Low to moderate absorption and systemic availability of WS400123 or components of it after oral or topical administration cannot be entirely discounted, because of its, possibly moderate, partition coefficient value (Log₁₀P_ow< 1), low water solubility (2.5 mg/L) and, to some extent, its molecular weight (ca. 300 – 600). An indication of systemic absorption of WS400123 or a small fraction of it after oral administration may be reductions in a number or red blood cell parameters attained in rats after 5 weeks of treatment by oral gavage. Some dermal absorption has been concluded from the sensitization response attained in a Local Lymph Node Assay (LLNA) in mice at non-irritating test concentrations of WS400123. 

 

Exposure of humans to WS400123 by the inhalation route is unlikely, because of its very low vapour pressure (1 x 10^-3Pa at 25°C), its decomposition at high temperature without boiling (above ca. 150°C) and because it is a highly viscous liquid.

 

All available study results gave no indication regarding the metabolic pathway, distribution or excretion of WS400123. Bioaccumulation was not investigated, but in view of its Log₁₀P_ow< +1, WS400123 is not considered to be bioaccumulative.